What does CD79b do?
CD79b: a B-cell surface antigen CD79b can be internalized upon antibody binding. Due to this functionality, CD79b has the potential to selectively deliver molecules of interest to B cells found in non-Hodgkin lymphomas (NHLs) such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
Is polivy a biologic?
The US FDA granted Priority Review for the company’s Biologics License Application for Polivy in February 2019.
Who makes polatuzumab?
Polatuzumab vedotin is being developed by Roche utilising Seattle Genetics ADC technology.
Is Mosunetuzumab FDA approved?
On July 14, 2020, the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to mosunetuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies.
What is LY6D?
LY6D (Lymphocyte Antigen 6 Family Member D) is a Protein Coding gene. Diseases associated with LY6D include Squamous Cell Carcinoma, Head And Neck. Among its related pathways are Metabolism of proteins and Post-translational modification- synthesis of GPI-anchored proteins. An important paralog of this gene is LYNX1.
Is polivy chemo?
Polivy is an antibody that is attached to a chemotherapy drug. Polivy binds to a specific protein (called CD79b) found only on B cells (a type of white blood cell), then releases the chemotherapy drug into those cells.
How is Mosunetuzumab administered?
Per study protocol, mosunetuzumab was administered with step-up dosing on days 1, 8, and 15 of cycle 1, followed by fixed doses on day 1 of each 21-day cycle, for up to 17 cycles.
What does positive for CD5 mean?
In adult human tissues, CD5 positive B cells have been reported to be present in the germinal centre and mantle zone. Malignancies of CD5 positive B cells include mantle cell lymphoma and chronic lymphocytic leukemia.